O
Olema Pharmaceuticals
Olema Pharmaceuticals, Inc.
About Olema Pharmaceuticals
Olema Pharmaceuticals, also known as Olema Oncology, is a clinical-stage biopharmaceutical company that operates in the healthcare sector, specifically in the field of oncology. The company's primary mission is to improve the lives of women living with cancer by developing targeted therapies. These therapies are designed to be more convenient and effective than current treatments, with the ultimate goal of transforming the standard of care for women with cancer.
Read full description
Olema Oncology's business model revolves around the discovery, development, and commercialization of these therapies. The company leverages its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance to achieve this. Essentially, they use their knowledge of how certain cancers work to create treatments that can better combat them.
The company's clients are primarily women living with cancer, a demographic that represents a significant portion of the global healthcare market. Olema Oncology generates revenue through the commercialization of its therapies, which involves selling them to healthcare providers or directly to patients.
Recently, Olema Oncology has reported positive results from a Phase 2 clinical study for one of its therapies, Palazestrant, and has made strategic appointments to its board of directors. These developments suggest that the company is making progress in its mission and is well-positioned for future growth.
At a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- San Francisco, United States
- Employees
- 172
- Open positions
- None listed
- Dealroom signal
- 55.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Olema Pharmaceuticals.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2020 | $54M | $216M | Wellington Management · BVF Partners · Citadel · Cormorant Asset Management | — |
| SERIES AOther financing | Aug 2018 | $6.1M | $24M | Undisclosed | — |
Growth signals
Latest recorded traffic for Olema Pharmaceuticals is 150 monthly website visits, down 69.4% over the last three months. Olema Pharmaceuticals's team grew 17% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Wellington Management
BVF Partners
Citadel
Cormorant Asset Management
Logos Capital
Venrock
Foresite Capital
RA Capital Management
Janus Henderson Investors
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Olema Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Olema Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.